San Francisco - based Harpoon Inc has raised about $ 76 m in an initial public offering , amid a biotech boom that shows no sign of slowing . The company offered 5.4 million shares at $ 1 per share , with trading launching on Nasdaq on Friday 8 February . Immunotherapy firm Harpoon focuses on the development of drugs called T cell killers , which use a patient 's T cells to locate and kill cancer cells . South San Francisco, CA-based Harpoon offered 5.4 million shares Thursday evening priced at $14 each, which was the midpoint of the range that the company had targeted. Its lead treatment , HPN424 , is currently in a phase one trial for patients with advanced prostate cancer .
San Francisco - based Harpoon Inc has raised about $ 76 m in an initial public offering , amid a biotech boom that shows no sign of slowing . The company offered 5.4 million shares at $ 1 per share , with trading launching on Nasdaq on Friday 8 February . Immunotherapy firm Harpoon focuses on the development of drugs called T cell killers , which use a patient 's T cells to locate and kill cancer cells . Its lead treatment , HPN424 , is currently in a phase one trial for patients with advanced prostate cancer .